welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Karen Anthony, PhD, FHEA, PgCert
Senior Lecturer in Molecular Bioscience
Molecular Biosciences Research Group Lead
Faculty of Health and Society
University of Northampton
Northampton, United Kingdom
Dr. Karen Anthony is currently working as senior lecturer in Molecular Bioscience at University of Northampton. She is a leading researcher on RNA processing and RNA-based therapeutics. Karen has worked on a number of neurological drug and disease targets including tau and TDP-43 for Alzheimer’s and motor neurone disease.
Her ongoing work is focused on the neuromuscular disorder, Duchenne muscular dystrophy (DMD). Karen played a key role in the clinical development of the first FDA-approved drug for DMD, an antisense oligonucleotide called Exondys 51 (eteplirsen).
She has developed, optimised and validated standardised protocols to accurately quantify dystrophin mRNA and protein in clinical trials and has helped international pharmaceutical companies with methodology for clinical trial biochemical outcome measures. Karen’s pre-clinical and clinical work in this area is helping to expedite the translation of exon skipping candidate drugs to the clinic.
Kay Davies, CBE, DBE, FMedSci, FRSDr. Kay Davies is elected Dr. Lee’s Pr...
Dongsheng Duan, PhDDr. Dongsheng Duan is Professor at Unive...
Yung-Yao Lin, BSc, PhDDr Lin made significant contributions in...
Sarepta Therapeutics and Genethon announce a gene therapy research collaboration for the treatment of Duchenne muscu...Sarepta Therapeutics, Inc. (NASDAQ:SRPT)...
Carrie Bunce, PTSchool based services...
Richard J. Barohn, MDRichard J. Barohn, MD, treats patients w...
U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editingA U.S. appeals court on Monday allowed a...